Literature DB >> 33799578

Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis.

Alina Agarkova1, Mikhail Pokrovskii1, Pavel Kolesnichenko1, Vladimir Gureev1, Oleg Gudyrev1, Anna Peresypkina1, Vladislav Soldatov1, Arkadii Nesterov2, Tatyana Denisyuk3, Mikhail Korokin1.   

Abstract

Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 × 109 CFU/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p < 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p < 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase-17%, superoxide dismutase-34%, malondialdehyde and acetylhydroperoxides-50%, and nitric oxide-85% (p < 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM.

Entities:  

Keywords:  bacterial meningitis; cerebroprotection; pneumococcal meningitis; treatment of bacterial meningitis

Year:  2021        PMID: 33799578      PMCID: PMC7998598          DOI: 10.3390/biomedicines9030285

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  19 in total

1.  [STUDYING SOME PHARMACOLOGICAL EFFECTS OF NEW 3-HYDROXYPYRIDINE DERIVATIVE].

Authors:  V V Yasnetsov; E G Tsublova; Vic V Yasnetsov; S Ya Skachilova; S K Karsanova; Yu V Ivanov
Journal:  Eksp Klin Farmakol       Date:  2016

2.  Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats.

Authors:  Tatiana Barichello; Jaqueline S Generoso; Cleonice M Michelon; Lutiana R Simões; Samuel G Elias; Franciele Vuolo; Clarissa M Comim; Felipe Dal-Pizzol; João Quevedo
Journal:  Exp Biol Med (Maywood)       Date:  2014-01-13

Review 3.  New understandings on the pathophysiology of bacterial meningitis.

Authors:  Uwe Koedel; Matthias Klein; Hans-Walter Pfister
Journal:  Curr Opin Infect Dis       Date:  2010-06       Impact factor: 4.915

Review 4.  Effect of vaccines on bacterial meningitis worldwide.

Authors:  Peter B McIntyre; Katherine L O'Brien; Brian Greenwood; Diederik van de Beek
Journal:  Lancet       Date:  2012-11-10       Impact factor: 79.321

Review 5.  Dilemmas in the diagnosis of acute community-acquired bacterial meningitis.

Authors:  Matthijs C Brouwer; Guy E Thwaites; Allan R Tunkel; Diederik van de Beek
Journal:  Lancet       Date:  2012-11-10       Impact factor: 79.321

6.  Factors influencing neurological outcome of children with bacterial meningitis at the emergency department.

Authors:  Fatiha Bargui; Irene D'Agostino; Patricia Mariani-Kurkdjian; Corinne Alberti; Catherine Doit; Nathalie Bellier; Laurence Morin; Giuliano Galli Gibertini; Assia Smail; Anna Zanin; Mathie Lorrot; Stéphane Dauger; Mathieu Neve; Albert Faye; Priscilla Armoogum; Antoine Bourrillon; Edouard Bingen; Jean-Christophe Mercier; Stéphane Bonacorsi; Lise E Nigrovic; Luigi Titomanlio
Journal:  Eur J Pediatr       Date:  2012-04-19       Impact factor: 3.183

7.  Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data.

Authors:  Diederik van de Beek; Jeremy J Farrar; Jan de Gans; Nguyen Thi Hoang Mai; Elizabeth M Molyneux; Heikki Peltola; Tim E Peto; Irmeli Roine; Mathew Scarborough; Constance Schultsz; Guy E Thwaites; Phung Quoc Tuan; A H Zwinderman
Journal:  Lancet Neurol       Date:  2010-02-03       Impact factor: 44.182

8.  Dexamethasone and long-term survival in bacterial meningitis.

Authors:  Daan Fritz; Matthijs C Brouwer; Diederik van de Beek
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

9.  Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis.

Authors:  Tobias Högen; Cornelia Demel; Armin Giese; Barbara Angele; Hans-Walter Pfister; Uwe Koedel; Matthias Klein
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

10.  Dexamethasone treatment and prognostic factors in community-acquired bacterial meningitis: a Danish retrospective population-based cohort study.

Authors:  Jacob Bodilsen; Michael Dalager-Pedersen; Henrik Carl Schønheyder; Henrik Nielsen
Journal:  Scand J Infect Dis       Date:  2014-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.